What is the primary difference in expense ratios between CNBS and MSOS?

CNBS charges an expense ratio of 0.76%, whereas MSOS charges 0.97%. This represents a difference of 0.21 percentage points. For investors, lower fees mean more of the fund's gross return is retained. While 0.21% seems small, it compounds over years. CNBS is the more cost-efficient option based strictly on these figures, assuming all other factors are equal.

How does the fund size difference between CNBS and MSOS affect liquidity?

MSOS has significantly more net assets at $976 million compared to CNBS's $78 million. Larger funds typically offer better liquidity, making it easier to buy or sell shares without impacting the price. CNBS's smaller size might limit trade execution speed for large orders. MSOS provides a more established platform due to its substantial asset base.

Why is the inception date relevant when comparing these cannabis ETFs?

CNBS launched in July 2019, while MSOS began in September 2020. The two-year gap gives CNBS a longer historical performance record. However, MSOS is still considered young in the broader context of fund investing. Longer track records provide more data for analysis, but past performance does not guarantee future results for either fund.

How do the top holdings of CNBS and MSOS compare?

Both funds list TRLV as a top holding, though weights differ. CNBS holds TRLV at 14.34%, while MSOS holds it at 11.47%. CNBS also includes IIPR and GRWG, adding diversity. MSOS focuses on US cannabis, implying a different underlying index or strategy. Investors should note that single-stock concentration affects risk in both funds.

What does the dividend yield indicate for these ETFs?

Both CNBS and MSOS report a dividend yield of 0.00%. This means they do not distribute regular income to shareholders. Investors seeking income must look elsewhere, as these funds reinvest earnings or hold no yield-generating assets like bonds. Total return depends solely on share price appreciation from the underlying cannabis sector stocks.

Which fund is better suited for US-specific cannabis exposure?

MSOS, named 'Pure US Cannabis', explicitly targets US-domiciled companies. CNBS, the Seymour Cannabis ETF, includes major Canadian platform exposure. If an investor seeks US market concentration, MSOS aligns with that goal. CNBS offers broader North American visibility, including significant Canadian holdings. Choice depends on the desired geographic focus within the sector.

How does cost efficiency influence long-term investment in these funds?

A higher expense ratio, like MSOS's 0.97% versus CNBS's 0.76%, reduces net returns annually. Over ten years, this 0.21% gap compounds, creating a noticeable difference in final portfolio value. Cost-conscious investors often prefer lower fees to maximize growth. However, fees alone do not determine performance quality, only retention of gross returns.

What is the geographic exposure difference between CNBS and MSOS?

CNBS provides exposure to Canadian platforms, highlighted by its holding in TRLV. MSOS targets US cannabis companies, aligning with its name. This geographic split is crucial for investors betting on regulatory or market trends in specific countries. Diversification between the two could mitigate regional risks, as each fund reacts to its home market's legislative changes.

How does sector concentration impact the risk profile of these ETFs?

Both funds are classified under Miscellaneous Sector, specifically cannabis. This narrow focus increases volatility compared to broad market ETFs. CNBS's additional holdings in IIPR and GRWG offer slight diversification within the niche. MSOS's single holding concentration in TRLV creates idiosyncratic risk. Sector downturns affect both, but individual stock shocks may impact one more heavily.

What are the implications of the shared top holding, TRLV?

TRLV is a shared top holding, appearing in both CNBS and MSOS. This overlap reduces the diversification benefit of holding both funds simultaneously. If TRLV underperforms, both portfolios will likely decline. Investors combining these ETFs should understand that they share common risk factors. The weight differences (14.34% vs 11.47%) slightly alter the impact magnitude.

Why should investors check the 'Index Tracked' data for these funds?

Currently, the index tracked is not available for both CNBS and MSOS. Understanding the underlying index helps clarify the fund's strategy and constituents. Without this, investors rely on top holdings and names for clues. This gap in data requires careful review of fund documents to ensure alignment with specific sector views or benchmarks.

What should beginners look for when comparing these two cannabis ETFs?

Beginners should compare expense ratios, net assets, and geographic focus. CNBS offers lower fees and a longer track record. MSOS provides higher liquidity and US-focused exposure. Checking top holdings reveals overlap in TRLV. Yield is zero for both. These factors help determine which fund matches an investor's risk tolerance and market view.

CNBS vs MSOS

Two funds, one decision: we compare cost, performance and what each ETF actually holds in October 2026.

This page compares CNBS and MSOS, examining fees, holdings and how each fund tracks its market. CNBS is an Amplify ETF with 0.76% expenses and $78 million in net assets, while MSOS has 0.97% expenses and $976 million. Both report zero dividend yield. TRLV is a shared top holding. Educational content, not financial advice.

This page compares CNBS and MSOS, examining fees, holdings and how each fund tracks its market. CNBS is an Amplify ETF with 0.76% expenses and $78 million in net assets, while MSOS has 0.97% expenses ...

Fund Snapshot

Key Fund Metrics

CNBS

Metric

MSOS

0.76%

Expense Ratio

0.97%

0.00%

Dividend Yield

0.00%

$77.68M

Net Assets

$976.02M

41

Holdings

106

Jul 23, 2019

Inception Date

Sep 1, 2020

–

Index Tracked

–

Miscellaneous Sector

Fund Category

Miscellaneous Sector

CNBS costs about $21.00 less per year for every $10,000 invested.

Shared Top Holdings

Holding	CNBS	MSOS
TRLVTrulieve Cannabis Corp.	14.34%	11.47%

Investment Analysis

CNBS

Pros

CNBS charges a 0.76% expense ratio, lower than many comparable sector ETFs.
Since July 2019, it offers a relatively long track record for niche investors.
Holding TRLV at 14.34% provides exposure to a major Canadian platform.

Considerations

With $78 million net assets, liquidity may be limited for large trades.
The fund pays no dividend, offering 0.00% yield for income-focused investors.
Top holdings are concentrated, with IIPR and GRWG adding less than 4% combined.

MSOS

Pros

MSOS benefits from substantial scale with $976 million in net assets.
It offers focused US exposure via its name and TRLV holding at 11.47%.
Although young, it tracks the popular US cannabis theme since September 2020.

Considerations

Its 0.97% expense ratio is higher than many broad market or niche funds.
The fund pays a 0.00% dividend yield, lacking regular income for holders.
Single holding concentration in TRLV increases idiosyncratic risk for the portfolio.

Related Market Insights

The Tax Rule That Broke Cannabis Is Finally Being Fixed

Discover how the US cannabis Schedule III reclassification removes the 280E tax burden and what it means for your investments. Invest in cannabis stocks on Nemo.

Aimee Silverwood | Financial Analyst

24 April 2026

Read Insight

Related Market Insights

The Tax Rule That Broke Cannabis Is Finally Being Fixed

Discover how the US cannabis Schedule III reclassification removes the 280E tax burden and what it means for your investments. Invest in cannabis stocks on Nemo.

Aimee Silverwood | Financial Analyst

24 April 2026

Read Insight

About CNBS and MSOS

CNBS (CNBS)

MSOS (MSOS)

Which Baskets Do They Appear In?

Cannabis Reclassification | Schedule III Tax Relief

The DOJ's historic move to reclassify marijuana as a Schedule III drug is removing massive tax burdens and sparking immediate optimism across the cannabis sector. This policy shift unlocks new profitability and operational pathways for medical producers, dispensaries, and pharmaceutical researchers navigating the newly regulated landscape.

Published: 24 April 2026

Explore Basket

Which Baskets Do They Appear In?

Cannabis Reclassification | Schedule III Tax Relief

The DOJ's historic move to reclassify marijuana as a Schedule III drug is removing massive tax burdens and sparking immediate optimism across the cannabis sector. This policy shift unlocks new profitability and operational pathways for medical producers, dispensaries, and pharmaceutical researchers navigating the newly regulated landscape.

Published: 24 April 2026

Explore Basket

CNBS vs MSOS

Fund Snapshot

Investment Analysis

CNBS

Pros

Considerations

MSOS

Pros

Considerations

Related Market Insights

The Tax Rule That Broke Cannabis Is Finally Being Fixed

Related Market Insights

The Tax Rule That Broke Cannabis Is Finally Being Fixed

About CNBS and MSOS

Which Baskets Do They Appear In?

Cannabis Reclassification | Schedule III Tax Relief

Which Baskets Do They Appear In?

Cannabis Reclassification | Schedule III Tax Relief

Buy CNBS or MSOS in Nemo

Zero Commission

Trusted & Regulated

6% Interest on Cash

Frequently asked questions

Fund Snapshot

About CNBS and MSOS

Which Baskets Do They Appear In?

Cannabis Reclassification | Schedule III Tax Relief

Which Baskets Do They Appear In?

Cannabis Reclassification | Schedule III Tax Relief

Related Market Insights

The Tax Rule That Broke Cannabis Is Finally Being Fixed

Related Market Insights

The Tax Rule That Broke Cannabis Is Finally Being Fixed